Stopping and restarting Mounjaro: what the evidence shows

What did @my.journey.with.marc actually say?

The creator claims there is no official guidance on how long you can pause Mounjaro or Wegovy, only a four-day window rule for missed doses. They say stopping GLP-1 medications is "not really a pause" but more like the body returning to baseline, with cravings potentially returning and the body reacting differently on restart. They frame this as something "no one really talks about."

To be fair, the creator is upfront that they are sharing personal experience alongside their interpretation of prescribing guidance. They do not claim clinical expertise. However, the video blends anecdote with medical framing in ways that deserve closer scrutiny, particularly the missed-dose rule and the claim about restarting on the same dose.

Does the science back this up?

Mostly, yes, on the pharmacology. Tirzepatide (Mounjaro) has a half-life of approximately five days, meaning it takes around four to five weeks for the drug to fully clear your system after stopping. The creator's framing of it as a gradual return to baseline is directionally correct.

The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) randomised participants who had lost weight on tirzepatide to either continue or switch to placebo. Those who stopped regained two-thirds of their lost weight over 88 weeks. This supports the creator's point that stopping is not a neutral event. Hunger and appetite regulation do shift when GLP-1 and GIP receptor agonism is removed.

The four-day missed-dose rule the creator cites is real. The Mounjaro prescribing information states that if more than four days have passed since a missed dose, skip it and resume on the regular schedule. This is accurately described.

What is less well-supported is the specific claim that restarting causes the body to "react completely differently." There is limited peer-reviewed evidence specifically on re-titration responses in people who have stopped tirzepatide for weeks. The SURMOUNT-4 re-treatment data is not yet widely published in a form that confirms materially different physiological responses on restart versus initial start.

What did they get wrong (or right)?

The creator gets the broad pharmacology right and deserves credit for not oversimplifying. Saying it is "not really a pause" is a more honest framing than much of the content circulating on GLP-1 TikTok.

However, the video implies that the prescribing guidance contains nothing beyond the four-day missed-dose rule. That is incomplete. Both the Mounjaro and Wegovy prescribing information contain dose titration schedules, and clinical guidance from bodies like the Obesity Medicine Association recommends stepping down to a lower dose after extended breaks, not simply resuming at the same dose. The creator does not mention this, and that omission matters practically.

The claim that restarting causes the body to "react completely differently" is presented with more certainty than the evidence warrants. It may be true for some people, particularly regarding gastrointestinal tolerance, but it is not an established physiological rule. Presenting personal observation as a general principle without that caveat is misleading.

The skin content is an advertisement. It is disclosed via a product mention but framed within a medical discussion in a way that blurs the line between health advice and promotion.

What should you actually know?

If you are considering stopping Mounjaro or semaglutide for any period, the most important thing to understand is that resuming at your previous dose after a break longer than one to two weeks carries real gastrointestinal risk. Nausea, vomiting and in rare cases more serious GI events are more likely if you restart at a higher dose without re-titrating.

Current clinical practice, based on the prescribing information and guidance from obesity medicine specialists, is to restart at the lowest dose (2.5mg for tirzepatide) and re-escalate according to tolerance if you have been off the medication for more than a few weeks. This is not mentioned anywhere in the video.

• Weight regain after stopping is well-documented and typically begins within weeks of discontinuation.
• The appetite-suppressing effects of tirzepatide are largely lost once the drug clears the system, around four to five weeks post-injection.
• There is no evidence that a short break resets tolerability to allow a higher dose on restart. If anything, re-titration is needed precisely because tolerance has been lost.
• Speak with your prescriber before making any changes to your injection schedule. Online communities and TikTok videos, including this one, are not substitutes for that conversation.